SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resection

Kevin N. Franks, Lucy McParland, Joanne Webster, David R. Baldwin, David Sebag-Montefiore, Matthew Evison, Richard Booton, Corinne Faivre-Finn, Babu Naidu, Jonathan Ferguson, Clive Peedell, Matthew E.J. Callister, Martyn Kennedy, Jenny Hewison, Janine Bestall, Walter M. Gregory, Peter Hall, Fiona Collinson, Catherine Olivier, Rachel Naylor, Sue Bell, Peter Allen, Andrew Sloss, Michael Snee

Source: Eur Respir J, 56 (5) 2000118; 10.1183/13993003.00118-2020
Journal Issue: November
Disease area: Thoracic oncology

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Kevin N. Franks, Lucy McParland, Joanne Webster, David R. Baldwin, David Sebag-Montefiore, Matthew Evison, Richard Booton, Corinne Faivre-Finn, Babu Naidu, Jonathan Ferguson, Clive Peedell, Matthew E.J. Callister, Martyn Kennedy, Jenny Hewison, Janine Bestall, Walter M. Gregory, Peter Hall, Fiona Collinson, Catherine Olivier, Rachel Naylor, Sue Bell, Peter Allen, Andrew Sloss, Michael Snee. SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resection. Eur Respir J, 56 (5) 2000118; 10.1183/13993003.00118-2020

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: